|

CME

PROGRAM EVALUATION AND REQUEST FOR CREDIT

We encourage all attendees to complete a program evaluation and request for CE credit. To collect your CE credits and certificate, click here. If you need help with your login information (account email or account password) please email iwcll2019@bioascend.com

 

TARGET AUDIENCE

Hematologists/oncologists who treat patients with CLL and researchers, oncology nurses, and pharmacists, and other clinicians and researchers with an interest in the biology, diagnosis, and treatment of CLL.

LEARNING OBJECTIVES:

After participating in the recommended activities, learners should be better able to:

Young Investigators Meeting

Evaluate and interpret the clinical significance of emerging evidence regarding:

  • Factors contributing to the development of CLL
  • The diagnosis, prognosis, and initial treatment of CLL
  • Factors contributing to disease evolution and progression
  • Treatment of advanced disease

Main Conference

Review recent clinical trial data of agents that target B-cell signaling pathways for the treatment of CLL

  • Evaluate apoptosis-inducing agents that are approved or undergoing examination in patients with CLL
  • Assess the role of monoclonal antibodies in the CLL treatment landscape, including their use as both monotherapy and in combination with other agents and regimens
  • Discuss the role of allogeneic stem cell transplant in the era of novel targeted therapies
  • Appraise recent clinical trial results of novel agents under investigation in patients with CLL
  • Examine the significance of MRD monitoring in CLL, and the role in treatment decisions and halting therapy
 

CONTINUING EDUCATION

EACCME

The XVIII International Conference on Chronic Lymphocytic Leukemia, Edinburgh, United Kingdom, 20/09/2019-23/09/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 27 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participationinternational-activities

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® forECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

ROYAL COLLEGE

XVIII International Conference on Chronic Lymphocytic Leukemiahas been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 25 category 1 (external) CPD credits.

 

DISCLOSURE OF RELATIONSHIPS WITH
COMMERCIAL INTERESTS

It is the policy of Bio Ascend, LLC to ensure balance, independence, objectivity, and scientific rigor in all activities. Individuals planning/developing content must disclose all relevant financial relationships or those of their spouse/ partner with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services influence practice and/or patient recommendations. Bio Ascend, LLC has taken steps to resolve all conflicts of interest.

DISCUSSION OF INVESTIGATIONAL AND OFFLABEL USAGE

This faculty may discuss unlabeled or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for approved indications, contraindications, and warnings.

DISCLAIMER

Participants have a responsibility to use newly acquired information to improve their practice and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.